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Abstract 
The predictive accuracy of the traditional staging system is based on disease progression as a tumour cell-autono-
mous process, but it fails to incorporate the effects of the host immune response. A precise analysis of the immune 
component of the tumour microenvironment by computer-based analysis may be essential to managing patients 
better, opening the road to an expertise in this new emerging field. The Immunoscore as a new possible approach in 
the classification of cancer, designated TNM-Immune, studied in colon cancer patients with predictive and prognostic 
value. This new scoring system is derived from the immune contexture, and is based on the numeration of lympho-
cyte populations, both in the core of the tumour and in the invasive margin of tumours. The Immunoscore demon-
strated to be quantitative, reproducible and robust. The usefulness of Immunoscore in advanced melanoma cancer 
patients has been as well demonstrated; the correlation of marker expression profile with clinical outcome is ongoing. 
More recently, the Immunoscore could be a useful prognostic marker in patients with rectal cancer treated by primary 
surgery. A multivariable Cumulative “Suppression Index” scoring system has been also studied in Oral Squamous 
Cell Carcinoma patients: it evaluates both the tumor and stromal microcompartments at the invasive margin and 
summarizes them into the score, providing an accurate stratification, independent of stage, tumour classification. 
The introduction of Immunoscore requires a redefinition of the Laboratory system according to the LEAN Manage-
ment process, which has been already implemented in referral research labs. The definition and test of hundreds of 
biomarkers, in the tumour contexture represents a definitive scientific progression. However, there is still a need of 
substantial body of work to reach the end of the tunnel to assure a personalize treatment.
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Introduction
The most used system for classifying the extent of can-
cer is the American Joint Committee on Cancer/Union 
Internationale Centre le Cancer (AJCC/UICC) Classifi-
cation of Malignant Tumours (TNM) classification, stag-
ing the tumour based on clonal tumour progression as 
reflected by the degree of locoregional involvement and 
on the acquisition of a set of unfavourable characteristics, 
such as the ability to invade lymphatic or blood vessels 
or to metastasize to distant sites. In daily practice and in 
guidelines, the TNM category is directly linked to treat-
ment strategies and, as such, changes in the TNM staging 
system have a considerable and direct impact on the can-
cer care that patients receive [1].
Unfortunately, the predictive accuracy of the tradi-
tional staging system assumes that disease progression is 
a tumour cell-autonomous process, but it fails to incor-
porate the effects of the host immune response. On the 
contrary, it is currently known that tumour progres-
sion should now be considered as the result of balance 
between an invasive tumour process and defence sys-
tem whose major component is constituted by the host 
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immune response [1]. Galon et al. proposed several ways 
to classify cancer based on tumour cell characteristics, 
including morphology, molecular pathways, mutation 
status, cell origin and gene expression-based methods, 
giving the possibility to distinguish among multiple, often 
overlapping, subtypes [1].
Modern classification of tumours is based on the 
recognition of disease entities that are characterized 
by morphological, phenotypical, and genetic markers. 
Each classification system needs to be reliable, repro-
ducible, clinically relevant, and biologically meaning-
ful. Many hurdles have to be taken into consideration, 
among them: (1) presence of non-neoplastic cells, 
including immune cells, making the ‘tumour areas’ not 
‘pure’ DNA (or RNA) areas and not solely comprised 
of neoplastic cells; (2) the requirement of immunohis-
tochemical techniques to enable the precise charac-
terization of specific tumour-infiltrating cells; (3) the 
need to select specific markers [1]. Recent publications 
indicated that a precise analysis of the immune com-
ponent of the tumour microenvironment by computer-
based analysis may be essential to managing patients 
better, opening the road to an expertise in this new 
emerging field.
The Worldwide Immunoscore consortium, includ-
ing 23 Centres in 17 countries, for more than 3000 
patients, composed of international expert pathologists 
and immunologists, identified a strategy for the organi-
zation of worldwide retrospective study for the valida-
tion of the Immunoscore in colon cancer. It defined, in 
different meetings held worldwide in the period Decem-
ber 2012–December 2015, with the support of the 
World Immunotherapy Council (WIC), of the Society 
for Immunotherapy of Cancer (SITC) and several other 
societies, the Immunoscore as a new possible approach 
in the classification of cancer, designated TNM-I (TNM-
Immune) [1].
This new scoring system is derived from the immune 
contexture, and is based on the numeration of two lym-
phocyte populations (CD3/CD45RO, CD3/CD8 or CD8/
CD45RO), both in the core of the tumour and in the 
invasive margin of tumours, as a clinically useful prog-
nostic marker in colorectal cancer. The Immunoscore 
provides a score ranging from Immunoscore 0 (I0) when 
low densities of both cell types are found in both regions, 
to Immunoscore 4 when high densities are found in both 
regions.
This test has a dual advantage: first, it appears to be 
the strongest prognostic factor for disease free survival 
(DFS), disease-specific (DSS) and overall survival (OS), 
including early-stage colorectal cancers; and second, it 
has biological meaning (adaptive immune response to 
tumours) and provides a tool or a target for novel thera-
peutic approaches, including immunotherapy (as recently 
illustrated in clinical trials boosting T cell responses with 
anti-CTLA4, anti-PDCD1 (PD-1) and anti-CD274 (PD-
L1). Current immunohistochemical technologies allow 
the application of such analyses in routine diagnostic 
pathology [1]. The main Immunoscore characteristics are 
reported in Table 1.
Unpublished data (Galon et  al. 2016) demonstrated 
the feasibility, reproducibility, significance, and robust-
ness of the Immunoscore in a worldwide study with a 
statistical analysis pre-defined plan (all statistical anal-
yses performed by external statisticians). The study 
primary endpoint was time-to-recurrence (TTR) for 
Immunoscore (High/Low) and inclusion criteria were 
colon cancer, stages I/II/III (T1–T4, N0–N2, M0), no 
neo-adjuvant treatments, clinical data and follow-up; 
exclusion criteria were rectum cancer stages IV (M1), 
neo-adjuvant treatments, missing clinical data, missing 
follow-up, staining intensity  <  152 and missing/incom-
plete biomarker data. 3855 patients were quantified for 
Immunoscore and 2667 patients were analysed after QC 
Table 1 Characteristics of a good marker and of the Immunoscore [8]
Characteristics
Routine Technic to be performed by pathologist using bright field and precise cell evaluation
Feasible Established pathology technics, using 2 regular whole slide FFPE section
Inexpensive Automatized immunohistochemistry
Rapid 2 simple staining less costly than complicated molecular techniques
Robust Autostainers, scanner, and digital pathology reduce the time to perform an Immunoscore
Reproducible Two strong membrane staining, with no background, allowing the numeration of individual cells
Quantitative Inter-observers variability is removed by the use of digital pathology, taking into account cell location and counts
Standardized Standardized operating procedure should be performed to insure reproducibility and worldwide comparisons
Pathology-based Necessity of pathologist expertise to validate cell type, cell location, and cell counts performed by digital pathology
Powerful The Immunoscore has a prognostic value highly significant even in Cox multivariate including TNM classification
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and exclusion following a pre-defined statistical analysis 
workplan. More than 352,000,000 CD3+  T cells were 
counted by all centres (Table 2).
Whole slide quantification demonstrated the best cor-
relation and reproducibility, proving that the Immu-
noscore is quantitative, reproducible and robust. The 
primary objective was reached: Immunoscore predicted 
time to recurrence on training set (TS), and on two inde-
pendent validation sets (IVS and EVS), blinded to clini-
cal outcome. Besides, multiple secondary objectives are 
reached Immunoscore 3 groups (and 5 groups); second-
ary objective as time to recurrence for Immunoscore 
(High/Int/Low) in Stage II objective was also reached. 
Immunoscore (2, 3, or 5 groups) is significant in multi-
variate analyses in TTR; similar results are found for DFS 
and OS. Immunoscore is significant in multivariate anal-
yses in OS, DFS, TTR (including MSI, T-stage, N-stage, 
age, gender). In conclusion, the primary endpoint of 
the Worldwide pre-specified Immunoscore study was 
reached; the TTR was significantly longer in patient’s 
stages I/II/III with High-Immunoscore; Low-Immu-
noscore identified a subgroup of patients with high-risk 
stage II colon cancer; Immunoscore was significant in 
multivariate analysis in all cohorts, TS, IVS and EVS and 
predicted TTR, DFS and OS.
The results of this international consortium may result 
in the implementation of the Immunoscore as a new 
component for the classification of cancer, designated 
TNM-I (TNM-Immune). This will represent the first 
standardized immune-based assay for the classification 
of cancer in the era of immunotherapy and will enable 
the classification cancer patients based on immune 
parameters.
Immunoscore will impact all types of cancer assess-
ment. For instance, Berghoff et  al. assessed the tumor-
infiltrating lymphocytes (TILs) in brain metastases (BM), 
one of the most common and devastating complication 
of cancer [2] by TIL subsets and their prognostic impact 
in 116 BM specimens using immunohistochemistry for 
CD3, CD8, CD45RO, FOXP3, PD1 and PD-L1. Immu-
noscore predicts overall survival and long-term survival 
in BM patients (HR 0.612, p < 0.001) [2].
Besides, findings indicate that assessment of the 
immune status via Immunoscore provides a potent 
indicator of colorectal tumour recurrence beyond Micro-
satellite-instability (Min) staging that could be an impor-
tant guide for immunotherapy strategies. Unpublished 
data from Mlecnik et al. reported that high immune cell 
densities and Immunoscore within the Min metastasis 
predicts prolonged survival.
It was demonstrated that the pre-existing immunity 
and the immune contexture predicts cancer survival [3] 
and allows to figure out major immune groups of patients 
(Fig. 1).
The stratification of cancer based on the immune sta-
tus underlines the importance of having standardized 
immune assays. Dr. Galon invited to collaborate at the 
evaluation of the role of Immunoscore on multiple can-
cers, in particular (among others) Melanoma, Cervi-
cal, Uterine, Liver, Pancreas in the Large retrospective 
cohorts (at all stages) with access to FFPE blocks, avail-
able clinical database and 5-year follow-up in order to 
review articles on Immunoscore in different cancer types, 
enhancing the topic of immune infiltrates as markers for 
tumor prognosis and/or response to therapy, stimulate 
international collaborations between research and clini-
cal investigators worldwide.
Immunoscore in melanoma
Might Immunoscore and Immunoprofiling be useful in 
melanoma for selecting patients? The subject has been 
studied since 1996 [4, 5] and the answer is definitively 
positive. Dr. Ascierto summarised Immunoscore and 
Immunoprofiling roles, underlining Immunoscore major 
utility (Table 3).
The potential prognostic value of CD3, CD8, CD20, 
and FOXP3 as an ‘Immunoscore’ for melanoma patients 
would utilize widely accessible, standardized technol-
ogy panel and conclude that it could be useful in defin-
ing the Immunoscore, because of its prognostic value in 
high risk melanoma patients. The prognostic and predic-
tive value of the Immunoscore in patients with advanced 
melanoma was furthermore assessed when treated with 
Ipilimumab in the previous 2–3  years [6]. The correla-
tion of marker expression profile with clinical outcome 
is ongoing. A trend for the CD163+  PD-L1+  (CT) 
population (p  =  0.07) is reported but no relationship 
with response/benefit [6]. A joint project between the 
Table 2 Biomarker characteristics results
Distribution of Immunoscore across all centres: High Immunoscore: 26%; Int. Immunoscore: 49%; Low Immunoscore: 25%
Number of CD3+ T cells/slide Whole slide density of CD3+ (cells/mm2) Whole slide density of CD8+ (cells/mm2)
Center 64,537 ± 80,962 685 ± 1297 239 ± 534
Margin 23,643 ± 23,524 1174 ± 1985 436 ± 832
Total 88,180 – –
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Fig. 1 Major immune groups [3–6, 9, 10]
Table 3 Immunoscore and Immunoprofiling differences
Immunoscore Immunoprofiling
Prognostic/predictive (?) Prognostic/predictive (?)
Number of Immunomarkers 2–4 1-several
Immunoscore markers CD3/CD8 Immune gene signatures
Immunoscore-like markers CD3/CD8/CD20/FoxP3 Multiplex assays
CD3/CD8/CD45RO CD137, Galectin1, LAG-3, OX40
PD-L1, TIM3 ect.CD3/CD8/CD68
CD3/CD8/CD20
CD3/GZMB
CD8/FoxP3
CD8/IL17
(others)
Possible applications • Staging in colorectal cancer (already tested) • Prognostic assay
• Staging in melanoma, breast cancer, Ovarian cancer,  NSCLC, prostate cancer, 
pancreatic cancer, head and neck cancer (to be defined)
• Diagnostic assay
• Personalized immune-treatment
Page 5 of 8Galon et al. J Transl Med  (2017) 15:212 
National Cancer Institute Pascale in Naples and the 
manufacturer Definiens assessed the correlation of cell 
density patterns with Ipilimumab patient overall sur-
vival. Prediction of survival based on immune biomark-
ers before and during treatment reported that before 
the treatment, short survival patients showed low fre-
quencies of circulating CD16+ CD56dim NK cells, high 
frequency of TIM-3+ CD56 bright NK cells, high expres-
sion levels of TIM-3 on both CD56 dim and CD56bright 
NK cells. After third cycle of treatment, it showed high 
TIM-3 expression on CD8+ T cells and on CD56dim NK 
cells inversely correlated with survival, the increased fre-
quency of KIR+ CD56dim circulating NK cells was asso-
ciated with adverse prognosis, the increased frequency 
of CD16+ CD56dim NK cells at this time point strongly 
correlated with good prognosis and long survival.
The Immunoscore for the immunomonitoring of colorectal 
cancer patients and Immunoscore beyond cancer
After years of controversy, immunotherapies have 
become the hot new thing in cancer drug development 
and Immunoscore is going to be implemented in the 
clinical practice, with the great support of clinicians 
and statisticians too. A prospective multicentre French 
study (NCT01688232) has been completed: 650 patients 
with colorectal cancer included, with median follow-up 
> 3 years (> 100 parameters monitored) to promote the 
Immunoscore in routine clinical settings.
In a first step, it has been decided not to consider rectal 
tumours due to distinct clinic pathologic features, tumor 
markers, and treatment regimens when compared with 
colonic adenocarcinomas. More recently, Anitei et  al. 
demonstrated that the Immunoscore could be a useful 
prognostic marker in patients with rectal cancer treated 
by primary surgery. The determination of the immune 
infiltrate in biopsies before treatment could be a valuable 
information for the prediction of response to pCRT [7].
The positioning of Immunoscore in colorectal patients 
is possible:
1. Patients with Low Immunoscore (high risk of 
relapse): more intensive treatment (stage II and stage 
III patients);
2. Patients with High Immunoscore (low risk of 
relapse): more lighter treatment (e.g. Folfox 3 months 
versus 6 months);
3. Evaluation of the risk of relapse of stage III patients 
with contraindication to chemotherapies.
A study is ongoing about the use of Immunoscore to 
predict non-cancer-related survival time: this is indicative 
of the host capacity to respond to immune challenges. This 
capacity could influence the incidence and/or severity of 
a large range of pathologies. The evidence seems to point 
towards an association of high immune infiltration means 
no longer non-cancer-related survival times and patients 
with a high density of cells for the adaptive immunity 
implies longer non-cancer-related survival times; finally, 
patients with a high immune infiltration plus a significant 
number of lympho nodes, implies a very long-life expec-
tancy. A possible major change of paradigm: the immune 
system is now recognized not only as a major player in the 
control of the tumour process but could also be integrated 
in the clinical practice to predict the outcome and influ-
ence treatment decisions beyond the cancer.
The discussion of Dr. Masucci from the Karolinska 
Institute provided interesting news about Immunoscore 
in the colorectal cancer. The prognostic and predictive 
impact of the Immune profile in colon cancer patients 
stage II and III was assessed in the Stockholm Cohort 
randomized to surgery or surgery and adjuvant treat-
ment. Genomic amplification of Immunohistochemistry 
was used to detect HLA-A2, MHC class I, HLA-G, MSI 
Her-3, CD8+  lymphocytes; time to relapse per age and 
per gender were assessed and no significant difference 
was found. Difference between stage II and III was sig-
nificant and treatment did not change the outcome as far 
as surgery alone versus surgery and adjuvant treatment.
Min has a relevant prognostic value in women but not 
in men in terms of time to relapse. Besides, CD8+ score 
is a stronger independent prognostic factor upon micros-
atellite instability scoring in women.
As far as HLA-A02 genotype and treatment, stage 
III patients with HLA-A02 genotype randomized to 
surgery had a worst outcome; this was not the case for 
patients with another HLA-A genotype. In the relation 
among HLA-A02 genotype, gender and treatment, the 
categories women, stage III, HLA-A02 genotype benefit 
to adjuvant cytostatic treatment but CD8+  infiltration 
prevent relapse of the tumour in women only in stage II 
women. Women treated with adjuvant treatment after 
surgery presenting high infiltration of CD8+  cells have 
the highest benefit. HLA-A status is more important than 
CD8+ for female subgroup.
Finally, CD8+  infiltration is predictive for survival in 
the all cohort (Table 4).
Absence of HLA-A02 genotype is predictive for 
good survival in the female subgroup compared to 
CD8+ (Table 5).
Table 4 CD8+ infiltration and survival (all cohort)
HR 95% CI p
HLA-Ax versus HLA-A2 0.859 0.516–1.430 0.5581
CD8+ infiltration at margin and in the 
tumour HIGH infiltration versus LOW
0.292 0.123–0.695 0.0054
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Implementation of the Immunoscore in a pathology lab 
based on the lean management system
Lean Management is a management philosophy devel-
oped from Toyota Production System focused on 
improving process speed and quality through reduction 
of process wastes. Basic concept for Lean management is 
a business methodology which aims at providing a new 
way to think about how to organize human activities to 
deliver more benefits to society and value to individuals 
while eliminating waste. It is therefore a systematic tool 
to eliminate waste which is caused by overburden and 
unevenness of work load.
The application of that to the cancer diagnosis and 
biomarkers, whose assessment is often characterized by 
small sample size, incomplete and not reproducible data, 
should be possible. In fact, an optimal biomarker study 
should be hypothesis driven, reproducible, with prognos-
tic and/or predictive power and cost-effective.
Some questions raise in the era of personalized health-
care, molecular medicine, digital pathology and automa-
tion: where will you implement the Immunoscore? Who 
is planning? Who is staining? Who is scanning? Who is 
analyzing? Who is controlling? Who is paying? In order 
to manage this personalized healthcare revolution a 
change of culture is required in pathology and it should 
involve creativity, leadership, and innovation.
The reorganization of the lab of the Institute of Pathol-
ogy, University of Bern, Bern, Switzerland, according to 
the Lean management, at implementation, allowed: (1) at 
operating level, the optimization of the rooms and work-
ing places, the optimization of the working process and 
the continuous working flow; (2) in the diagnostic wing, 
in the six standardized sign-out rooms, optimal teaching 
and quality control; (3) in the Lean lab, working with the 
LEAN Tissue Street (LTS) defined as LEAN Biopsy Street 
(LBS) and LEAN Resection Street (LRS).
The Lean management approach allows to implement 
the Immunoscore workflow, according to the here below 
reported interactions (Fig. 2).
Suppressive Index: another side of the Immunoscore
The Immunoscore developed by Galon and colleagues, 
quantitative assessment of CD3+  and CD8+  T cells at 
the invasive margin and tumor center is revolutionizing 
the field of predictive and prognostic biomarker discov-
ery of immune subsets within the tumor, and encourag-
ing the adoption of digital pathology tools for biomarker 
discover and validation. Currently, CD8+  T cell infil-
trates have been shown to have prognostic value in vari-
ous types of cancer, including melanoma, NSCLC, RCC 
and bladder cancer. Quantitative IHC assessment can 
also be predictive, as high densities of CD8 and PD-L1 
staining correlate with response to anti-PD-1 immuno-
therapy agents. However, many patients, with high levels 
of T cell infiltrates in their tumors, rapidly progress, and 
other patients, with tumors that have high PD-L1 expres-
sion, don’t respond to anti-PD L1 therapy. Therefore, it 
can be hypothesized that the tumor is characterized by 
a complex microenvironment that is difficult to describe 
with single markers such as CD8+ and PD-L1, and that 
the utilization of multiparametric analysis to study the 
interactions and spatial relationships between tumour 
and immune cell types could describe the complex land-
scape of the tumour microenvironment, helping to more 
accurately stratify the patients compared to CD8 and/or 
CD3 alone.
Changes in the composition and function of innate and 
adaptive immune cells in the tumour microenvironment 
represent crucial hallmarks for initiation and progression 
of cancer. In Oral Squamous Cell Carcinoma (OSCC) the 
composition, frequency and location of peri- and intra-
tumoral immune cells, but also the expression of HLA 
class I antigens and other components of the antigen 
processing machinery by tumour cells, play an impor-
tant role in the control of HPV-positive tumours, but the 
prognostic and therapeutic impact of these parameters in 
HPV-negative OSCC has not yet been clarified. A mul-
tivariable Cumulative “Suppression Index” (CSI) scoring 
system (Fig. 3) allowed to separate OSCC patients with a 
5-year overall survival rate (OSR) of 90 and 20%, respec-
tively. Multispectral imaging enabled the simultaneous 
evaluation of immune and tumor cells interactions and 
their use as prognostic biomarkers in evaluating OSCC 
patients’ outcome, by focusing on the microenvironment 
centred around CD8+  effector cells. Building on con-
cepts that Galon and colleagues have established previ-
ously in their studies on colon carcinoma, the combined 
Table 5 CD8+ infiltration and survival (female)
HR 95% CI p
HLA-Ax versus HLA-A2 0.405 0.160–1.027 0.5569
CD8+ infiltration at margin and in the 
tumour HIGH infiltration versus LOW
1281 0.246–6.679 0.7686
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“suppression index” evaluates both the tumor and stro-
mal microcompartments at the invasive margin and sum-
marizes them into CSI (Fig. 3). This provided an accurate 
stratification, independent of stage, separating patients 
with over 90% 5-year survival from those with only 20% 
5-year survival in the study’s cohort. Incorporating tumor 
levels of beta-2-m, MHC class I HC and LMP10 further 
improved the prognostic power, identifying 5-year OS 
rates of 0 to 100% (p < 0.001).
Finally, understanding the nature of T-cell suppressive 
signals active in the tumor microenvironment may enable 
a rational approach to combination immunotherapies.
Scientists have been very successful to define and 
test hundreds of biomarkers, in the tumour contexture, 
Fig. 2 Lean Management applied to the Immunoscore
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Immunoscore is an example of a validated markers for 
colon cancer (predictive and prognostic). However, there 
is still a need of substantial body of work to reach the end 
of the tunnel to assure a personalize treatment.
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Fig. 3 Cumulative Suppressive Index (CSI): multiparametric analysis 
of the interactions and spatial relationships of both the tumor and 
stromal microcompartments at the invasive margin
